Efficient inhibition of in-stent restenosis by controlled stent-based inhibition of elastase: A pilot study

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 11, 2004, Pages 1287-1293

  Ganaha, Fumikiyo ^a   Ohashi, Kazuo ^a   Do, Young So ^a   Lee, Jane ^a   Sugimoto, Koji ^a   Minamiguchi, Hiroki ^a   Elkins, Christopher J ^a   Sameni, Diba ^a   Modanlou, Shoreh ^a   Ali, Mir ^b   Kao, Edward Y ^a   Kay, Mark A ^a   Waugh, Jacob M ^a   Dake, Michael D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ELASTASE; ELASTASE INHIBITOR; ELASTIN; MACROGOL; MICROSPHERE; POLYGLACTIN; POLYMER;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INTIMA; AORTA MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ELUTING STENT; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IMPLANTATION; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RABBIT; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 8444231583     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000141340.67588.4F     Document Type: Article

References (50)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496-501.
2. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med 1999; 341: 1957-1965.
3. Jacobs AK. Coronary stents - have they fulfilled their promise? N Engl J Med 1999; 341:2005-2006.
4. Bauters C, Banos JL, Van Belle E, Fadden EP, Lablanche JM, Bertrand ME. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation 1998; 97:318-321.
5. Yutani C, Imakita M, Ishibashi-Ueda H, Tsukamoto Y, Nishida N, Ikeda Y. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol Int 1999; 49:273-290.
6. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J Am Coll Cardiol 1997; 30:186-192.
7. Hoffman R, Minz GS, Dussaillant GR, et al. Patterns and mechanisms of instent restenosis: a serial intravascular ultrasound study. Circulation 1996; 94: 1247-1254.
8. Strauss BH, Robinson R, Batchelor WB, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996; 79: 541-550.
9. Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. Atherosclerosis 1998; 140:281-295.
10. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118:253-256.
11. Skinner MP, Raines EW, Ross R. Dynamic expression of α1β1 and α2β1 integrin receptors by human vascular smooth muscle cells. Am J Pathol 1994; 145:1070-1081.
12. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the αV/β3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I. Proc Natl Acad Sci U S A 1996; 93: 2482-2487.
13. Bingley JA, Campbell JH, Hayward IP, Campbell GR. Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann N Y Acad Sci 1997; 811:238-244.
14. Batchelor WB, Robinson R, Strauss BH. The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention. Prog Cardiovasc Dis 1998; 41:35-49.
15. Ooyama T, Fukuda K, Oda H, Nakamura H, Hikita Y. Substratum-bound elastin peptide inhibits aortic smooth muscle cell migration in vitro. Arteriosclerosis 1987; 7:593-598.
16. Barolet AW, Nili N, Cheema A, et al. Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler Thromb Vasc Biol 2001; 21:1269-1274.
17. Thompson K, Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix-bound basic fibroblast growth factor. J Cell Physiol 1996; 166:495-505.
18. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 1988; 106:1659-1665.
19. Yuksel E, Weinfeld A, Cleek R, et al. Increased free fat-graft survival with the long-term, local delivery of insulin, insulin-like growth factor-1, and basic fibroblast growth factor by PLGA/PEG microspheres. Plast Reconstr Surg 2000; 105:1712-1720.
20. Ponder KP, Gupta S, Leland F, et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci U S A 1991; 88:1217-1221.
21. Elkins CJ, Waugh JM, Amabile PG, et al. Development of a platform to evaluate and limit in-stent restenosis. Tissue Eng 2002; 8:395-407.
22. Waugh JM, Li-Hawkins J, Yuksel E, et al. Therapeutic elastase inhibition by alpha-1-antitrypsin gene transfer to limit neointima formation in normal rabbits. J Vasc Interv Radiol 2001; 12: 1203-1209.
23. Waugh JM, Li-Hawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neointima formation. Circulation 2000; 102:332-337.
24. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenacin-C antisense prevents progression, of vascular disease. J Clin Invest 2000; 105:21-34.
25. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circulation Res 1994; 75:650-658.
26. Cowan B, Baron O, Crack J, Coulber C, Wilson GJ, Rabinovitch M. Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J Clin Invest 1996; 97: 2452-2468.
27. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinase 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999; 99: 3199-3205.
28. Li DY, Brook B, Davis EC, et al. Elastin is an essential determinant of arterial morphogenesis. Nature 1998; 383: 276-280.
29. Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. Atherosclerosis 1198; 140:821-895.
30. Oho S, Rabinovitch M. Post-cardiac transplant arteriopathy in piglets is associated with fragmentation of elastin and increased activity of a serine elastase. Am J Pathol 1994; 145:202-210.
31. Hinek A, Boyle J, Rabinovitch M. Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced "shedding" of the 67-kDa cell surface elastin binding protein. Exp Cell Res 1992; 203:344-353.
32. Hinek A, Mecham RP, Keeley F, Rabinovitch M. Impaired elastin fiber assembly related to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured aortic smooth muscle cells treated with chondroitin sulfate. J Clin Invest 1991; 88: 2083-2094.
33. Hinek A, Molossi S, Rabinovitch M. Functional interplay between interleukin-1 receptor and elastin binding protein regulates fibronectin production in coronary artery smooth muscle cells. Exp Cell Res 1996; 225:122-131.
34. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
35. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87:1069-1078.
36. Simon DI, Ezratty AM, Francis SA, Rennke H, Locals J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993; 82:2414-2422.
37. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996; 16:28-33.
38. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29:808-816.
39. Alt E, Haehnel I, Beilharz C, et al. Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000; 101:1453-1458.
40. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998; 32:780-786.
41. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103:192-195.
42. Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the Sirius trial. J Am Coll Cardiol 2004; 43:1959-1963.
43. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109:2273-2278.
44. Doggrell SA. Sirolimus- versus paclitaxel-eluting stent in patients with stenosis in a native coronary artery. Exp Opin Pharmacother 2004; 5:1431-1434.
45. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942-1947.
46. Silber S, Hamburger J, Grube E, et al. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II. Herz 2004; 29:171-180.
47. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109:487-493.
48. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stent: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 2004; 109:196-200.
49. Buellersfeld L, Grube E. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz 2004; 29:167-170.
50. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109:2168-2171.